Inside the Pet Supplement Industry: $2.4B and Growing

Consumer Alerts · 7 min read

The pet supplement industry is no longer a niche corner of the pet store. It is a $2.4 billion market in the United States alone, growing at 7-9% annually, attracting venture capital, private equity, and strategic acquisition by multinational consumer goods corporations. The category has professionalized, consolidated, and — in many respects — outpaced the regulatory framework meant to oversee it.

Understanding the industry’s structure, economics, and trajectory is not academic. It directly affects what products are available, how they are marketed, what claims they make, and how much you pay. This report maps the landscape.

Market Size and Growth

Current Valuation

Multiple market research firms converge on similar figures:

• Grand View Research (2025): U.S. pet supplements valued at $2.38 billion.
• Mordor Intelligence (2025): $2.41 billion, with global market at $4.87 billion.
• Statista (2025): U.S. pet vitamins and supplements revenue at $2.3 billion.

The canine segment represents approximately 60-65% of the total, with feline at 25-30% and other species (equine, avian, small mammal) comprising the remainder.

Growth Projections

Consensus forecasts project the U.S. market reaching $3.8-4.2 billion by 2030, representing a compound annual growth rate (CAGR) of 7-9%. This outpaces overall pet industry growth (5-6%) and significantly outpaces human supplement growth (4-5%).

Category Breakdown

By product type, the canine supplement market segments approximately as:

• Joint health (glucosamine, chondroitin, MSM, omega-3): ~30-35% of market
• Digestive health (probiotics, prebiotics, enzymes): ~20-25%
• Skin and coat (omega fatty acids, biotin): ~15-18%
• Calming and behavior (L-theanine, CBD, chamomile): ~10-12%
• Immune support (antioxidants, vitamins, mushrooms): ~8-10%
• Senior/cognitive health (MCT oil, phosphatidylserine): ~5-7%
• Oral health: ~3-5% (significantly underrepresented relative to disease prevalence)
• Multivitamins and general wellness: ~5-8%

Growth Drivers

1. Pet Humanization

The structural driver underlying all others: pets are increasingly positioned as family members rather than animals. The American Pet Products Association reports that 66% of U.S. households own a pet, and spending per pet has increased 40% since 2015 (inflation-adjusted). Owners who consider dogs “children” apply human health-consumption patterns: preventive supplementation, ingredient scrutiny, and willingness to pay premium prices for perceived quality.

2. Aging Pet Population

Advances in veterinary medicine have extended average canine lifespan. Dogs living to 12-15 years develop age-related conditions (osteoarthritis, cognitive decline, cardiac disease) that owners seek to manage preventively. The “senior dog” supplement segment is the fastest-growing subcategory (12-15% CAGR).

3. Digital-First Distribution

Subscription DTC models (auto-ship, subscribe-and-save) reduce purchase friction and create recurring revenue. Chewy’s autoship program, Amazon Subscribe & Save, and brand-owned subscription platforms have shifted purchasing from episodic (pet store visit) to habitual (monthly delivery). This favors supplement products — consumable, repeatable, shippable — over durable goods.

4. Social Media and Influencer Marketing

Instagram, TikTok, and YouTube pet influencers drive product discovery. “Pet parent” content creators with 100K-5M followers promote supplements through sponsored posts, affiliate links, and “honest review” formats. The marketing cost per acquired customer through influencer channels is often lower than traditional advertising, making it attractive for DTC startups.

5. Preventive Health Mindset

The cultural shift from reactive treatment (“see the vet when something is wrong”) to proactive prevention (“supplement daily to avoid problems”) mirrors the human wellness movement. Supplements are positioned as affordable insurance against future veterinary costs — a $30/month chew versus a $3,000 surgery.

Key Players and Competitive Structure

Legacy Animal Health Companies

• Nutramax Laboratories: Maker of Cosequin and Dasuquin (joint), Proviable (probiotics). Veterinary-channel dominant. Acquired by Boehringer Ingelheim in 2022 for ~$1.2 billion.
• Zesty Paws (Health & Happiness International): DTC pioneer, Amazon-dominant. Acquired by H&H International (also owns Swisse human supplements) in 2021 for ~$550 million.
• VetriScience (FutureCeuticals): Veterinary-channel supplements. Broad portfolio across categories.

Multinational Entrants

• Mars Petcare: Greenies (dental), plus supplement line extensions under Pedigree and IAMS brands.
• Nestlé Purina: Pro Plan supplements, FortiFlora (probiotic). Leveraging veterinary nutrition research infrastructure.
• Colgate-Palmolive (Hill’s): Science Diet supplement additions, prescription-adjacent products.
• J.M. Smucker (Rachael Ray Nutrish, 9Lives): Supplement-fortified food and treat products.

DTC Startups and Venture-Backed Brands

The 2019-2025 period saw an influx of venture-funded DTC pet supplement brands, typically characterized by:

• Subscription-first business model
• Instagram/TikTok-native marketing
• “Clean label” positioning (no fillers, no artificial ingredients)
• Aggressive affiliate programs (30-50% commission)
• Contract manufacturing (few own production facilities)
• Rapid SKU expansion across categories

Not all survive. The DTC pet supplement space has seen significant churn, with brands launching, scaling through paid acquisition, and either achieving profitability or being acquired/shut down within 3-5 years.

Private Label and Contract Manufacturing

A significant portion of the market is produced by a small number of contract manufacturers:

• Manufacturing concentration: An estimated 60-70% of U.S. pet supplement SKUs are produced by fewer than 20 contract manufacturing facilities, primarily in Utah, New Jersey, and Florida.
• Private label: Retailer brands (Chewy, PetSmart, Costco/Kirkland, Amazon) source from the same manufacturers as branded products, with different labeling and minor formulation variations.
• Implication: Products from seemingly unrelated brands may share manufacturing lines, base formulations, and quality-control infrastructure.

Consolidation Trends

Acquisition Activity (2020-2026)

The pet supplement space has experienced significant M&A activity:

• 2021: H&H International acquires Zesty Paws (~$550M)
• 2022: Boehringer Ingelheim acquires Nutramax (~$1.2B)
• 2023: Multiple mid-market acquisitions by private equity firms targeting DTC pet health brands
• 2024-2025: Continued roll-up activity; PE firms assembling “platforms” of complementary pet health brands

Drivers of Consolidation

• Scale economics: Larger entities negotiate better raw material pricing, manufacturing rates, and retail placement.
• Channel access: Acquiring a DTC brand provides direct consumer data; acquiring a veterinary-channel brand provides clinic distribution.
• Portfolio breadth: Multi-category portfolios reduce customer acquisition cost through cross-selling.
• Exit liquidity: Venture-backed founders seek exits; strategic buyers (Mars, Nestlé, Boehringer) pay premiums for growth-stage brands.

Consumer Implications

Consolidation is neither inherently beneficial nor harmful to consumers, but it changes the landscape:

• Quality investment: Larger owners may fund clinical trials, stability testing, and quality infrastructure that startups cannot afford.
• Reduced differentiation: As brands consolidate under common ownership, product formulations may converge. “Competing” brands on the shelf may share a parent company.
• Marketing sophistication: Corporate marketing departments bring larger budgets, more sophisticated targeting, and greater capacity to shape consumer perception.
• Price pressure: Reduced competition in consolidated segments can lead to price increases without corresponding quality improvements.

The Regulatory Environment

As documented in our regulatory analysis, the pet supplement industry operates with minimal pre-market oversight. The FDA does not approve supplements before sale. AAFCO provides guidelines without enforcement. NASC offers voluntary certification covering a fraction of the market.

This regulatory environment has enabled rapid market entry and innovation. It has also enabled:

• Products with unverified label claims
• Inconsistent quality between batches
• Marketing that outpaces evidence
• Contamination incidents detected only post-market

The industry’s growth has outpaced regulatory capacity. Whether this gap closes through increased FDA enforcement, new legislation, or industry self-regulation remains an open question as of 2026.

What This Means for Consumers

• More choice does not mean more quality. The proliferation of SKUs reflects marketing segmentation, not necessarily scientific differentiation. Many products are minor variations of the same base formulation.
• Price is not a reliable quality signal. Premium pricing may reflect marketing costs, packaging, and brand positioning rather than ingredient quality or clinical evidence.
• Corporate ownership affects incentives. A venture-backed brand under pressure to show growth metrics may prioritize customer acquisition over product development. A legacy company with veterinary-channel reputation has different incentive structures.
• Independent verification matters more as the market grows. With thousands of SKUs and limited regulatory oversight, the burden of quality assessment falls on the consumer. Third-party testing, published evidence, and transparent sourcing become essential evaluation criteria.

The Bottom Line

The pet supplement industry is a $2.4 billion market growing faster than the regulatory framework designed to oversee it. It is consolidating under corporate ownership, professionalizing its marketing, and expanding its product universe faster than the evidence base can support.

None of this makes supplements inherently bad. Many products are well-formulated, appropriately dosed, and genuinely beneficial. But the market’s structure — growth-driven, marketing-intensive, lightly regulated — creates conditions where commercial incentives can outpace scientific justification.

The informed consumer navigates this landscape by asking: what is the evidence for this specific product? Who verified its contents? What does the corporate structure incentivize? And who benefits most from my purchase — my dog, or the affiliate who recommended it?